00 · At a glance
Two pan-RAS drugs showed pancreatic cancer data, both single-arm. Actinogen’s Alzheimer’s trial missed.
Bookmarks need a Mind Club sign-in. How sign-in works
At a glance across your briefsErasca reports confirmed responses in 44% of 25 previously treated pancreatic cancer patients; Revolution Medicines reports 60.7% first line with chemotherapy. Stocks fell again on Thursday, and the VIX rose to 28.44.
- XBI · 11.19
- 1D −0.6% · 1W −4.7% YTD +18.2%
- 144.12
- IBB · 11.19
- 1D −0.8% · 1W −4.6% YTD +20.7%
- 203.72
- UST 10-YEAR
- 11.19 · FROM 5.07% ON 11.18 2Y 4.76% · 2S10S +28BP
- 5.04%
- US BIOTECH IPOS YTD
- ~$8.2B RAISED MIND CLUB TALLY · 11.20
- 30
Market figures as of the 11.19 close: XBI and IBB closes from Robinhood market data; Treasury yields from the U.S. Treasury daily par yield curve (11.19 and 11.18); IPO count and proceeds from the Mind Club financing tally (US sheet, IPOs of $5M or more, 11.20). SPY, IWM, fed funds and the VIX print in 01 Markets & outlook. Facts only, not a view on any security.
Verification at a glance
- CLAIM CHECK
- 2 match · 2 partial · 1 open
- 5
- CALENDAR DATES
- confirmed at the source
- 18/22
- REGISTRY WATCH
- trials · 0 changes · full table in 14B
- 70
- OPEN CALLS
- none resolved today · see 15
- 3
- CORRECTIONS
- none new · see 16
- 17
The five-minute readThree that matter · one date · one open question
| # | What happened | So what · our analysis | Priority · sources | Page |
|---|---|---|---|---|
| 01 | Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients at 32 mg, its chosen dose. The Phase 1 trial has no control group, and response rate is a secondary endpoint. | Single-arm, early and company-reported, so it cannot show benefit over other treatment. Erasca plans a first-line pancreatic Phase 3 in the first half of 2027. | Must read CoReg | 08 |
| 02 | Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer. In 61 patients, 60.7% had a confirmed response and median progression-free survival was 12.8 months. | Another single-arm result. The randomized test against chemotherapy alone, RASolute 303, has not read out. | Must read CoReg | 08 |
| 03 | Actinogen’s pivotal trial of Xanamem in Alzheimer’s disease missed its primary endpoint. The benefit on CDR-SB at week 36 was 0.10 points versus placebo, p = 0.65. | The company points to a prespecified subgroup of older patients, but a subgroup after a missed primary is a reason for a new trial, not proof. | Must read CoReg | 09 |
| + | Also today. 04 Regeneron’s Livsayis (cemdisiran), an RNAi drug from Alnylam, was approved for generalized myasthenia gravis. 05 AbbVie took an option to license AND-gated bispecifics from DISCO, with $40M upfront; Bloomberg reports Sanofi is weighing a bid for Insmed. | 09 | ||
| DATE | One date to hold. Fri 11.27: FDA goal date for BridgeBio’s BBP-418 in limb-girdle muscular dystrophy 2I/R9, per BridgeBio. More in 14. | 18 | ||
| OPEN | The open question. Does adding a pan-RAS drug to first-line chemotherapy help patients live longer? Both of today’s RAS results are single-arm; RASolute 303, randomized against chemotherapy alone with survival as a co-primary, is designed to test it for daraxonrasib; primary completion is estimated for 04.2028. | 17 |
HOW TO READ THIS BRIEF
Must readunderstand today. Know itsecondary. Scanawareness only. Verified a primary source was checked, Claim a company statement, Analysis our interpretation, Forecast a dated judgment with odds. Red boxes are the red team. Source badges: Reg trial registry Gov agency or government Peer peer-reviewed journal Pre preprint Co company or organizer release or filing Data curated database Press journalism. Claim Check verdicts compare a headline with the registered protocol: MatchPartialMismatchOpen. A verdict says what differs, never why.
Reading priority index
- Must readERAS-0015 in pancreatic cancer · Daraxonrasib first line · Xanamem misses · Claim Check · Target Evidence Card
- Know itLivsayis approval · AbbVie and DISCO, Sanofi and Insmed · Policy & regulatory watch · Verified Catalyst Calendar
- ScanBright spot · Registry Watch · Public Calls Ledger